List view / Grid view
26 January 2015 | By NewCap.
Santen SAS announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the granting of a marketing authorization for Ikervis®...
23 January 2015 | By Novartis
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Jakavi® (ruxolitinib) for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea...
Cocrystals can help to address the manufacturability (flow, compaction, processability) as well as solubility/dissolution,hygroscopicity and stability properties of an active pharmaceutical ingredient (API).
8 December 2014 | By Astellas
Astellas Pharma Europe Ltd. announced that the European Commission (EC) has granted a variation to amend the Marketing Authorisation for enzalutamide (trade name XTANDI™)...
2 December 2014 | By Inventiva
This follows an earlier positive opinion for IVA337 in October regarding the treatment of Systemic Sclerosis (SSc)...
1 December 2014 | By Janssen-Cilag International
Janssen-Cilag International NV (Janssen) announced today the submission of a Type II variation application to the European Medicines Agency (EMA) to vary the marketing authorisation for IMBRUVICA® (ibrutinib), to include a new therapeutic indication, the treatment of adult patients with Waldenström’s macroglobulinemia (WM). If approved, this latest regulatory submission will…
1 December 2014 | By Treeway
Treeway B.V. is pleased to announce that the European Medicines Agency has granted orphan drug designation for TW001 for the treatment of ALS...
19 November 2014 | By MSD
Application for approval of new indication for golimumab has been filed with the European Medicines Agency...
4 November 2014 | By Andrew Lloyd & Associates
With few approved drugs available in SSc, this approach could significantly improve the treatment options in the future...
3 November 2014 | By Birken
Birken AG, a biopharmaceutical and dermo-cosmetic company, announces that the European Medicines Agency has accepted its Oleogel-S10 Marketing Authorization Application for review...
27 October 2014 | By The Institute of Cancer Research
The European Medicines Agency has approved olaparib for women with ovarian cancer who have a BRCA mutation - the first time a cancer drug has been approved targeted at an inherited genetic fault...
27 October 2014 | By Clinuvel Pharmaceuticals Limited
The first new pharmaceutical drug invented and developed for an untreated disorder by any Australian company has received regulatory approval from the European Medicines Agency (EMA). SCENESSE® (afamelanotide 16mg) treats the debilitating genetic disorder porphyria (EPP), or absolute intolerance to sunlight...
24 October 2014 | By European Medicines Agency
Rapid scientific advice to speed up development...
21 October 2014 | By The European Medicines Agency
EMA encourages companies to apply for orphan designation...
29 September 2014 | By Janssen
Janssen-Cilag International NV announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has granted a Positive Opinion recommending REZOLSTA™...
